|
Apr 29
|
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
|
|
Apr 29
|
TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025…
|
|
Apr 24
|
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
|
|
Feb 29
|
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
|
|
Feb 28
|
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
|
|
Feb 28
|
Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial
|
|
Feb 28
|
Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation
|
|
Feb 27
|
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
|
|
Feb 26
|
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
|
|
Feb 25
|
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
|
|
Jan 9
|
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia
|
|
Jan 2
|
Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL
|
|
Dec 20
|
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million
|
|
Dec 20
|
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia
|
|
Dec 4
|
TNXP: Topline Results from Phase 3 RESILIENT Study in Fibromyalgia Expected in Late December 2023…
|
|
Dec 4
|
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
|
|
Nov 28
|
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
|
|
Sep 6
|
Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January...
|
|
Sep 5
|
UPDATE 1-Tonix's long COVID drug fails to meet mid-stage trial goal
|
|
Sep 5
|
Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID
|